Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||4SC-205 + Ceritinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|4SC-205||LH031|4SC205|4SC 205|SC-205||4SC-205 inhibits human kinesin-related motor protein Eg5, which may lead to cell cycle arrest and apoptosis in tumor cells (NCI Drug Dictionary).|
|Ceritinib||Zykadia||LDK378||ALK Inhibitor 31 ROS1 Inhibitor 20||Zykadia (ceritinib) inhibits ALK, including ALK mutations and fusions, and has additional activity against ROS1 fusions, potentially resulting in decreased tumor cell growth (PMID: 25322323, PMID: 26372962). Zykadia (ceritinib) is FDA approved for ALK-positive (rearrangements and fusions) metastatic non-small cell lung cancer (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ALK F1174L||neuroblastoma||sensitive||4SC-205 + Ceritinib||Preclinical - Cell culture||Actionable||In a preclinical study, the combination of 4SC-205 and Zykadia (ceritinib) inhibited viability to a greater degree than either therapy alone in neuroblastoma cell lines harboring ALK F1174L (PMID: 34709738).||34709738|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|